Summary of COVID-19 azelastine studies
Studies
Meta Analysis
Hide extended summaries
Retrospective 219,000 patients showing lower risk of COVID-19 with antihistamine H1RA use. In Vitro study showing these drugs exhibit direct antiviral activity against SARS-CoV-2. Molecular docking suggests hydroxyzine and azelastine may exert antiviral effects by binding ACE2 and the sigma-1 receptor.
Jan 2021, Biochemical and Biophysical Research Communications, https://www.sciencedirect.com/science/article/pii/S0006291X20321409, https://c19p.org/reznikovazl
251 patient azelastine late treatment RCT: 13% improved recovery (p=0.42) and 6% improved viral clearance (p<0.0001).
RCT 294 low-risk subjects with mild COVID-19 showing significantly greater reduction in viral load with azelastine 0.1% nasal spray vs. placebo. There was no COVID-19 related hospitalization in either group. The reduction in viral load was significantly higher in the azelastine group at day 3, 6 and 11. Authors report that treatment was associated with significant improvement in fever, weakness, and hypoxia compared to placebo, however detailed results are not provided for these and other symptoms. Treatment delay from symptom onset is not specified, however the baseline viral load, lack of progression, and recovery profile are consistent with relatively late treatment among low-risk patients. Time to recovery results are not clear, with an inconsistent HR and 95% CI reported 0.32 [0.83-2.32].
Oct 2024, Viruses, https://www.mdpi.com/1999-4915/16/12/1914, https://c19p.org/meiserazl
RCT 90 outpatients showing potential benefit of azelastine nasal spray for reducing viral load. Patients were randomized to receive placebo, 0.02%, or 0.1% azelastine nasal spray for 11 days. The 0.1% azelastine group showed greater viral load reduction compared to placebo (p=0.007) and achieved PCR negativity earlier (48.2% vs 23.1% negative by day 11). Symptoms improved across all groups, with the 0.1% group showing slightly greater improvement (12.74 point reduction vs 11.12 for placebo) and significantly better improvement in shortness of breath on days 3-4. No significant differences were found in quality of life measures or WHO clinical progression scores.
Apr 2023, Scientific Reports, https://www.nature.com/articles/s41598-023-32546-z, https://c19p.org/klussmannazl
1. Reznikov et al., Identification of antiviral antihistamines for COVID-19 repurposing
azelastine prophylaxis study: 45% fewer cases (p=0.03).Retrospective 219,000 patients showing lower risk of COVID-19 with antihistamine H1RA use. In Vitro study showing these drugs exhibit direct antiviral activity against SARS-CoV-2. Molecular docking suggests hydroxyzine and azelastine may exert antiviral effects by binding ACE2 and the sigma-1 receptor.
Jan 2021, Biochemical and Biophysical Research Communications, https://www.sciencedirect.com/science/article/pii/S0006291X20321409, https://c19p.org/reznikovazl
251 patient azelastine late treatment RCT: 13% improved recovery (p=0.42) and 6% improved viral clearance (p<0.0001).
RCT 294 low-risk subjects with mild COVID-19 showing significantly greater reduction in viral load with azelastine 0.1% nasal spray vs. placebo. There was no COVID-19 related hospitalization in either group. The reduction in viral load was significantly higher in the azelastine group at day 3, 6 and 11. Authors report that treatment was associated with significant improvement in fever, weakness, and hypoxia compared to placebo, however detailed results are not provided for these and other symptoms. Treatment delay from symptom onset is not specified, however the baseline viral load, lack of progression, and recovery profile are consistent with relatively late treatment among low-risk patients. Time to recovery results are not clear, with an inconsistent HR and 95% CI reported 0.32 [0.83-2.32].
Oct 2024, Viruses, https://www.mdpi.com/1999-4915/16/12/1914, https://c19p.org/meiserazl
3. Klussmann et al., Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients
61 patient azelastine early treatment RCT: 13% improved recovery (p=0.54) and 14% improved viral clearance (p=0.22).RCT 90 outpatients showing potential benefit of azelastine nasal spray for reducing viral load. Patients were randomized to receive placebo, 0.02%, or 0.1% azelastine nasal spray for 11 days. The 0.1% azelastine group showed greater viral load reduction compared to placebo (p=0.007) and achieved PCR negativity earlier (48.2% vs 23.1% negative by day 11). Symptoms improved across all groups, with the 0.1% group showing slightly greater improvement (12.74 point reduction vs 11.12 for placebo) and significantly better improvement in shortness of breath on days 3-4. No significant differences were found in quality of life measures or WHO clinical progression scores.
Apr 2023, Scientific Reports, https://www.nature.com/articles/s41598-023-32546-z, https://c19p.org/klussmannazl
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.